3rd May 2016 07:58
LONDON (Alliance News) - PureTech Health PLC on Tuesday said its Gelesis business has received positive results from its first in-human study of diabetes product Gelesis200.
Gelesis200 is a oral capsulated device that seeks to induce weight loss and improve glycaemic control in patients with type 2 diabetes.
PureTech said the study demonstrated positive safety and tolerability, with no serious adverse events reported.
"Gelesis will now be able to assess Gelesis200 in a three-month proof-of-concept study, with the goal of ultimately offering a novel weight management and glycaemic control product for patients with type 2 diabetes," PureTech Executive Vice President Of Science And Technology Eric Elenko said in a statement.
Shares in PureTech were trading flat at 130.00 pence on Tuesday morning.
By Karolina Kaminska; [email protected] @KarolinaAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
PureTech